Content deleted Content added
Citation bot (talk | contribs) Added date. Removed parameters. | Use this bot. Report bugs. | Suggested by GrapesRock | #UCB_toolbar |
Added short description Tags: Mobile edit Mobile app edit Android app edit App suggested edit App description add |
||
| (2 intermediate revisions by one other user not shown) | |||
Line 1:
{{Short description|France-based pharmaceutical group}}
{{Infobox company
|name = Advanced Accelerator Applications
Line 14 ⟶ 15:
The group operates in all three segments of nuclear medicine ([[Positron emission tomography|PET]], [[SPECT]] and [[radionuclide therapy|therapy]]) to diagnose and treat serious conditions in the fields of [[oncology]], [[neurology]], [[cardiology]], infectious and inflammatory [[diseases]].<ref name="AAA2">[http://www.ilsole24ore.com/art/impresa-e-territori/2014-03-12/dal-cern-biopark-canavese-064227.shtml?uuid=ABvohR2&fromSearch Il Sole 24 Ore, "Dal Cern and Biopark canavese", March 12th, 2014]</ref>
In late October 2017, ''[[Reuters]]'' announced that [[Novartis]] would acquire the company for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium.<ref>{{Cite news|url=http://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|archive-url=https://web.archive.org/web/20201205154247/https://uk.reuters.com/article/uk-novartis-advanced-accelerator/novartis-to-buy-frances-advanced-accelerator-for-3-9-billion-idUKKBN1CZ0KM|url-status=dead|archive-date=December 5, 2020|title = Novartis to buy French cancer specialist AAA for $3.9 billion|newspaper = Reuters|date = 3 November 2017|last1 = Miller|first1 = John}}</ref> On January 22, 2018, Novartis AG announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A.<ref>{{Cite press release |title=Novartis Completes Tender Offer for Advanced Accelerator Applications |date=23 January 2018 |publisher=Novartis |url=https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period}}</ref>
==History==
Line 40 ⟶ 41:
==== Approval ====
Lutathera, also known as [[lutetium]] Lu 177 dotatate, is a target treatment drug for patients with [[Neuroendocrine tumor|GEP-NETs]].<ref name=":0">{{Cite web|url=https://www.cancer.gov/news-events/cancer-currents-blog/2018/lutathera-fda-gastrointestinal-nets|title=FDA Approves New Treatment for Neuroendocrine Tumors|website=National Cancer Institute|date=8 February 2018|language=en|access-date=2018-05-26}}</ref> Its approval for Advanced Accelerator Applications was announced on January 26, 2018, by the [[Food and Drug Administration|US Food and Drug Administration]].<ref name=":1">{{Cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm|archive-url=https://web.archive.org/web/20180128055839/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm|url-status=dead|archive-date=January 28, 2018|title=Press Announcements - FDA approves new treatment for certain digestive tract cancers|last=Commissioner|first=Office of the|website=www.fda.gov|language=en|access-date=2018-05-26}}</ref> Lutathera is most notable as the first FDA approved peptide receptor [[radionuclide]] therapy (PRRT) to combat GEP-NETs.<ref name=":2">{{Cite web|url=https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutatherar-treatment-gastroenteropancreatic-neuroendocrine-tumors|title=Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors {{!}} Novartis|website=Novartis|language=en|access-date=2018-05-26}}</ref>
===== GEP-NETs =====
| |||